Business Of Biotech podkast

Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.

Do tyłu o 15 sekund
Do przodu o 15 sekund

We love to hear from our listeners. Send us a message.

Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necessary companion diagnostic arena. On today’s episode of the Business of Biotech, recorded in San Francisco, we sit down with Dr. Mark Hoppin, CEO of Ratio Therapeutics, a company that’s well-positioned in the space with a fresh Series B and the foundation of a tunable radiotherapeutic that Dr. Hoppin says addresses the delivery, safety and efficacy challenges long associated with radiopharmaceuticals in the treatment of solid cancers. We also discuss how this mathemetician-turned biotech CEO has navigated the leadership of boards, employees, and investors on his journey.

You've listened along for years -- now you can watch along, too! Go to, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at!

Więcej odcinków z kanału "Business Of Biotech"